StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) shareholders

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.1%
0M of 15M shares
Institutional holders
25
2 new, 5 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Robert J. Eide
Joint filing with Pembroke & Partners LLC (9.99%)
16,895,7129.99%13D (active) amendmentApr 8, 2025
Stern Adam K2,972,5249.99%13D (active) amendmentJun 10, 2026
Hezbay Holdings LLC1,306,4889.54%13G (passive)Jul 13, 2026
Lazar David E.545,0009.81%13G (passive)Aug 15, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of MTNBValueChange% of portfolio
Renaissance Technologies LLC4,7360.03%$43.48K+2,8310.00%
BlackRock, Inc.3,3510.02%$30.76K+410.00%
Geode Capital Management, LLC3,2760.02%$30.08K−1,0680.00%
Vanguard Capital Management LLC2,6740.02%$24.55K–0.00%
Holos Integrated Wealth LLC2,1650.01%$20.17K–0.01%
Vanguard Fiduciary Trust Co1,1540.01%$10.60K−640.00%
Susquehanna International Group, Llp1,0730.01%$9.85K+1180.00%
Citadel Advisors LLC1,0310.01%$9.47K−2,4160.00%
State Street Corp1,0210.01%$9.38K–0.00%
Sargent Investment Group, LLC8480.01%$7.79K–0.00%
Tower Research Capital LLC (TRC)1900.00%$1.75K–0.00%
Vanguard Global Advisers, LLC890.00%$819–0.00%
Morgan Stanley230.00%$211–0.00%
Costello Asset Management, INC130.00%$122–0.00%
Wells Fargo & Company/Mn70.00%$62–0.00%
Jones Financial Companies Lllp40.00%$39–0.00%
EverSource Wealth Advisors, LLC40.00%$37–0.00%
Vision Financial Markets LLC30.00%$26–0.00%
Osaic Holdings, Inc.30.00%$31–0.00%
Rothschild Investment LLC10.00%$9–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026250M0.1%2 / 33 / 50M0M
Q1 2026280M0.2%5 / 27 / 50M0M
Q4 2025300M0.2%8 / 43 / 60M0M
Q3 2025280M0.1%5 / 71 / 10M0M
Q2 2025240M0.1%3 / 33 / 40M0M
Q1 2025250M0.1%5 / 53 / 20M0M
Q4 2024220M0.2%8 / 17 / 30M0M
Q3 2024170M0.2%17 / 00 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jerome D. JabbourPresident and CEO, Director810,0115.51%May 2, 2025
An Evelyn DDirector––Nov 9, 2026
Edward NeugeborenDirector––Nov 9, 2026
Keith MurphyDirector––Nov 9, 2026
Robin L. SmithDirector––May 2, 2025
Partners LLC Sanitam10% owner––Aug 13, 2026
Adam K. Stern10% owner1,231,4458.38%Aug 13, 2026
& Partners LLC Pembroke10% owner––Apr 10, 2025
Robert J. Eide10% owner3,0000.02%Apr 10, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Adam K. Stern
10% owner
Jul 10, 2026Option exercise+344,710$0.35$120.65K416,900
Adam K. Stern
10% owner
Jul 10, 2026Option exercise+630,335$0.35$220.62K743,785
Adam K. Stern
10% owner
Oct 31, 2025Option exercise+92,100$0.64$58.94K113,450
Herbert J. Conrad
Director
Jun 22, 2022Gift+1,358,122––4,694,566
Herbert J. Conrad
Director
Jun 22, 2022Gift−1,358,122––0
Matthew Wikler
Director
Dec 31, 2021Award+7,859––290,472
Matthew Wikler
Director
Sep 30, 2021Award+6,106––282,613
Raphael J. Mannino
Chief Scientific Officer
Sep 3, 2021Other+462,150––1,919,715
Herbert J. Conrad
Director
Aug 4, 2021Gift−494,622––0
Herbert J. Conrad
Director
Aug 4, 2021Gift+494,622––3,336,444
Herbert J. Conrad
Director
Jul 7, 2021Gift−1,280,917––1,358,122
Herbert J. Conrad
Director
Jul 7, 2021Gift+1,280,917––2,841,822
Matthew Wikler
Director
Jun 30, 2021Award+10,244––276,507
Jerome D. Jabbour
President and CEO, Director
Jun 19, 2021Other+6,000––810,011
Jerome D. Jabbour
President and CEO, Director
Jun 19, 2021Conversion+30,000––840,011
Eric J. Ende
Director
Jun 19, 2021Conversion+24,000––144,092
Eric J. Ende
Director
Jun 19, 2021Other+4,800––120,092
Matthew Wikler
Director
Jun 19, 2021Other+2,400––254,263
Matthew Wikler
Director
Jun 19, 2021Conversion+12,000––266,263
Raphael J. Mannino
Chief Scientific Officer
Jun 19, 2021Conversion+20,000––1,457,565
Raphael J. Mannino
Chief Scientific Officer
Jun 19, 2021Other+8,000––1,437,565
James S. Scibetta
Director
Jun 19, 2021Other+4,800––625,958
James S. Scibetta
Director
Jun 19, 2021Conversion+24,000––649,958
Herbert J. Conrad
Director
Jun 19, 2021Conversion+200,000––1,560,905
Herbert J. Conrad
Director
Jun 19, 2021Other+40,000––1,360,905
Herbert J. Conrad
Director
May 20, 2021Gift+1,145,905––1,320,905
Herbert J. Conrad
Director
May 20, 2021Gift−1,145,905––0
Matthew Wikler
Director
Mar 31, 2021Award+7,560––251,863
Herbert J. Conrad
Director
Jan 13, 2021Gift−50,000––494,622
Herbert J. Conrad
Director
Jan 13, 2021Gift+50,000––175,000
Matthew Wikler
Director
Dec 31, 2020Award+11,673––244,303
Matthew Wikler
Director
Sep 30, 2020Award+20,725––232,630
Adam K. Stern
Director
Aug 21, 2020Buy+20,000$0.83$16.60K3,301,983
Matthew Wikler
Director
Jun 30, 2020Award+20,537––211,905
Raphael J. Mannino
Chief Scientific Officer
Jun 23, 2020Other+3,000––1,429,565
Herbert J. Conrad
Director
Jun 23, 2020Other+30,000––544,622
Jerome D. Jabbour
President and CEO, Director
Jun 23, 2020Other+4,500––804,011
James S. Scibetta
Director
Jun 23, 2020Other+3,600––621,158
Matthew Wikler
Director
Jun 23, 2020Other+1,800––191,368
Eric J. Ende
Director
Jun 23, 2020Other+3,600––115,292
Adam K. Stern
Director
Jun 23, 2020Other+25,500––3,281,983
Herbert J. Conrad
Director
Jun 4, 2020Gift−2,639,039––125,000
Herbert J. Conrad
Director
Jun 4, 2020Gift+2,639,039––2,639,039
Patrick G. Lepore
Director
May 14, 2020Buy+100,000$0.73$73.00K400,000
Herbert J. Conrad
Director
May 13, 2020Gift+2,639,039––2,764,039
Herbert J. Conrad
Director
May 13, 2020Gift−2,639,039––1,145,905
Adam K. Stern
Director
Apr 3, 2020Option exercise+278,407$0.50$139.20K1,337,399
Matthew Wikler
Director
Mar 31, 2020Award+26,450––189,568
Adam K. Stern
Director
Mar 17, 2020Buy+10,000$0.65$6.50K10,000
Jerome D. Jabbour
President and CEO, Director
Mar 17, 2020Buy+10,000$0.65$6.50K799,511
Matthew Wikler
Director
Dec 31, 2019Award+6,994––163,118
James S. Scibetta
Director
Dec 31, 2019Award+8,260––617,558
Herbert J. Conrad
Director
Dec 31, 2019Award+10,573––514,622
Keith A. Kucinski
Chief Financial Officer
Nov 25, 2019Buy+58,000$1.23$71.34K94,500
Keith A. Kucinski
Chief Financial Officer
Nov 22, 2019Buy+36,500$1.20$43.80K36,500
Patrick G. Lepore
Director
Nov 15, 2019Buy+100,000$1.06$106.00K300,000
Herbert J. Conrad
Director
Sep 30, 2019Award+38,066––504,049
James S. Scibetta
Director
Sep 30, 2019Award+29,739––606,898
Matthew Wikler
Director
Sep 30, 2019Award+25,179––154,924
Eric J. Ende
Director
Aug 20, 2019Buy+20,000$0.66$13.20K109,292

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
0.24%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-28.1%
From 0M shares
Short volume, 20 days
37.4%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Matinas BioPharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 64,559 shares on Sep 15, 2026 over the last 90 days.

See a number that looks wrong?